Literature DB >> 23813136

Serum cholesterol is a significant and independent mortality predictor in liver cirrhosis patients.

Martin Janičko1, Eduard Veselíny, Dušan Leško, Peter Jarčuška.   

Abstract

BACKGROUND AND AIM: Accurate assessment of cirrhotic patient's prognosis is essential for decisions regarding the course of treatment. Therefore we aimed to confirm and quantify the predictive value of serum cholesterol and serum triglycerides in liver cirrhosis patients.
MATERIAL AND METHODS: We performed a retrospective observational cohort study on consecutive patients with liver cirrhosis (n = 191). Relevant clinical and laboratory variables were obtained from patients' charts and patients were followed for two months. Mortality was the main outcome.
RESULTS: Thirty-eight patients died in the follow-up period. Significant difference was observed in the level of total serum cholesterol between surviving and deceased patients (2.27 ± 1.02 mmol/L vs. 2.97 ± 1.00 mmol/L, P < 0.0001 respectively). Cholesterol was confirmed as a significant predictor of mortality in univariate logistic regression analysis, and independent predictor beside bilirubin, creatinine and MELD score in multivariate logistic regression analysis. Addition of serum cholesterol level to a prognostic model based on total bilirubin, creatinine and INR increased its accuracy by 4%. Adding cholesterol to the MELD score improved prediction accuracy by 3%. There was no significant difference in serum levels of triglycerides between surviving and deceased patients.
CONCLUSION: Serum cholesterol is a routinely measured parameter, which has independent prognostic value in patients with liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23813136

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  8 in total

1.  Circulating mortalin autoantibody--a new serological marker of liver cirrhosis.

Authors:  Wen-Jing Lu; Nishant Saxena; John M Luk; Sunil C Kaul; Renu Wadhwa
Journal:  Cell Stress Chaperones       Date:  2015-04-24       Impact factor: 3.667

2.  Spike-and-slab type variable selection in the Cox proportional hazards model for high-dimensional features.

Authors:  Ryan Wu; Mihye Ahn; Hojin Yang
Journal:  J Appl Stat       Date:  2021-03-04       Impact factor: 1.416

Review 3.  Pleiotropic effects of statins in the diseases of the liver.

Authors:  Martin Janicko; Sylvia Drazilova; Daniel Pella; Jan Fedacko; Peter Jarcuska
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

4.  Lipid profile in cirrhotic patients and its relation to clinical outcome.

Authors:  Laura Boemeke; Lilian Bassani; Cláudio Augusto Marroni; Catarina Bertaso Andreatta Gottschall
Journal:  Arq Bras Cir Dig       Date:  2015 Apr-Jun

5.  Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis.

Authors:  Nahum Méndez-Sánchez; Eira Cerda-Reyes; Fátima Higuera-de-la-Tijera; Ana K Salas-García; Samantha Cabrera-Palma; Guillermo Cabrera-Álvarez; Carlos Cortez-Hernández; Luis A Pérez-Arredondo; Emma Purón-González; Edgar Coronado-Alejandro; Arturo Panduro; Heriberto Rodríguez-Hernández; Vania C Cruz-Ramón; Alejandro Valencia-Rodríguez; Xingshun Qi; Nashla Hamdan-Pérez; Nancy E Aguilar-Olivos; Beatriz Barranco-Fragoso; Oscar Ramírez-Pérez; Alfonso Vera-Barajas
Journal:  F1000Res       Date:  2020-01-28

6.  Low PCSK9 levels are correlated with mortality in patients with end-stage liver disease.

Authors:  Valentin Schlegel; Theresa Treuner-Kaueroff; Daniel Seehofer; Thomas Berg; Susen Becker; Uta Ceglarek; Joachim Thiery; Thorsten Kaiser
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

7.  Observation of the effect of the pregnancy complicated with the hepatitis B infection on the lying-in women and neonates.

Authors:  Bo Xiao; Ailing Liu; Ming Zhang; Hui Xue; Yi Zhu
Journal:  Saudi J Biol Sci       Date:  2019-08-27       Impact factor: 4.219

8.  Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis B virus infection.

Authors:  Li-Ting Yan; Li-Li Wang; Jia Yao; Ya-Ting Yang; Xiao-Rong Mao; Wei Yue; Yong-Wu Mao; Wei Zhou; Qing-Feng Chen; Yu Chen; Zhong-Ping Duan; Jun-Feng Li
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.